Oligonucleotide-based Theranostic Nanoparticles in Cancer Therapy

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2016 Apr 23

PMID 27102380

Citations 10

Authors

Reza Shahbazi

Bulent Ozpolat

Kezban Ulubayram

Affiliations

Soon will be listed here.

Abstract

Theranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic agents, have been effectively employed in theranostic systems against various cancers. Nanoparticles are used to deliver oligonucleotides into tumors by passive or active targeting while protecting the oligonucleotides from nucleases in the extracellular environment. The use of quantum dots, iron oxide nanoparticles and gold nanoparticles and tagging with contrast agents, like fluorescent dyes, optical or magnetic agents and various radioisotopes, has facilitated early detection of tumors and evaluation of therapeutic efficacy. In this article, we review the advantages of theranostic applications in cancer therapy and imaging, with special attention to oligonucleotide-based therapeutics.

Citing Articles

Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.

Wu Y, Shang J, Zhang X, Li N J Nanobiotechnology. 2024; 22(1):783.

PMID: 39702277 PMC: 11657939. DOI: 10.1186/s12951-024-02940-4.

LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation.

He S, Huang G, Lei R, Jia R, He Z, Chen J Acta Pharm Sin B. 2024; 14(7):2942-2958.

PMID: 39027255 PMC: 11252458. DOI: 10.1016/j.apsb.2024.04.023.

Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential.

Alors-Perez E, Pedraza-Arevalo S, Blazquez-Encinas R, Moreno-Montilla M, Garcia-Vioque V, Berbel I J Exp Clin Cancer Res. 2023; 42(1):282.

PMID: 37880792 PMC: 10601233. DOI: 10.1186/s13046-023-02858-z.

Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer.

Abate M, Lombardi A, Luce A, Porru M, Leonetti C, Bocchetti M Mol Ther Nucleic Acids. 2023; 33:127-141.

PMID: 37449042 PMC: 10336355. DOI: 10.1016/j.omtn.2023.06.012.

Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.

Tabasi H, Mollazadeh S, Fazeli E, Abnus K, Taghdisi S, Ramezani M Appl Biochem Biotechnol. 2023; 196(3):1685-1711.

PMID: 37402038 DOI: 10.1007/s12010-023-04597-5.

References

Yu B, Tai H, Xue W, Lee L, Lee R . Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27(7):286-98. PMC: 3789246. DOI: 10.3109/09687688.2010.521200. View

Taylor R, Huber D, Monson T, Ali A, Bisoffi M, Sillerud L . Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res. 2011; 13(10):4717-4729. PMC: 3223933. DOI: 10.1007/s11051-011-0439-3. View

Reischl D, Zimmer A . Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine. 2008; 5(1):8-20. DOI: 10.1016/j.nano.2008.06.001. View

Zhu D, Liu F, Ma L, Liu D, Wang Z . Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agents. Int J Mol Sci. 2013; 14(5):10591-607. PMC: 3676856. DOI: 10.3390/ijms140510591. View

Khanna S, SPEISER P . Epoxy resin beads as a pharmaceutical dosage form. I. Method of preparation. J Pharm Sci. 1969; 58(9):1114-7. DOI: 10.1002/jps.2600580916. View

Lin C, Zhong Z, Lok M, Jiang X, Hennink W, Feijen J . Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug Chem. 2007; 18(1):138-45. DOI: 10.1021/bc060200l. View

Mertz D, Tan P, Wang Y, Goh T, Blencowe A, Caruso F . Bromoisobutyramide as an intermolecular surface binder for the preparation of free-standing biopolymer assemblies. Adv Mater. 2011; 23(47):5668-73. DOI: 10.1002/adma.201102890. View

Kirtane A, Panyam J . Polymer nanoparticles: Weighing up gene delivery. Nat Nanotechnol. 2013; 8(11):805-6. DOI: 10.1038/nnano.2013.234. View

Ki M, Kim J, Lee Y, Noh S, An S, Cho H . Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy. Pharm Res. 2014; 31(12):3323-34. DOI: 10.1007/s11095-014-1422-3. View

10.

Li J, Gu M . Surface plasmonic gold nanorods for enhanced two-photon microscopic imaging and apoptosis induction of cancer cells. Biomaterials. 2010; 31(36):9492-8. DOI: 10.1016/j.biomaterials.2010.08.068. View

11.

Chan W, Nie S . Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998; 281(5385):2016-8. DOI: 10.1126/science.281.5385.2016. View

12.

de Barros A, Tsourkas A, Saboury B, Nascimento Cardoso V, Alavi A . Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res. 2012; 2(1):39. PMC: 3441881. DOI: 10.1186/2191-219X-2-39. View

13.

Swierczewska M, Lee S, Chen X . Inorganic nanoparticles for multimodal molecular imaging. Mol Imaging. 2011; 10(1):3-16. PMC: 3629957. View

14.

Wang J, Lu Z, Wientjes M, Au J . Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010; 12(4):492-503. PMC: 2977003. DOI: 10.1208/s12248-010-9210-4. View

15.

Brignole C, Marimpietri D, Gambini C, Allen T, Ponzoni M, Pastorino F . Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 2003; 197(1-2):199-204. DOI: 10.1016/s0304-3835(03)00099-5. View

16.

Cullen B . Transcription and processing of human microRNA precursors. Mol Cell. 2004; 16(6):861-5. DOI: 10.1016/j.molcel.2004.12.002. View

17.

Zolata H, Abbasi Davani F, Afarideh H . Synthesis, characterization and theranostic evaluation of Indium-111 labeled multifunctional superparamagnetic iron oxide nanoparticles. Nucl Med Biol. 2014; 42(2):164-70. DOI: 10.1016/j.nucmedbio.2014.09.007. View

18.

Yuan H, Zhang W, Du Y, Hu F . Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery. Int J Pharm. 2010; 392(1-2):224-31. DOI: 10.1016/j.ijpharm.2010.03.025. View

19.

Tekedereli I, Alpay S, Tavares C, Cobanoglu Z, Kaoud T, Sahin I . Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171. PMC: 3401164. DOI: 10.1371/journal.pone.0041171. View

20.

Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno N . Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010; 9(5):1180-7. DOI: 10.1158/1535-7163.MCT-09-1025. View